Choice can get this wrong — tell us if something's off.
1–20 of 31
EducationConfirmedIn favor
Lilly awards over $458 million in college scholarships
Lilly awarded more than $458 million through the competitive College and Community Collaboration initiative to 19 Indiana colleges and universities across two rounds.
Through the competitive College and Community Collaboration initiative, Lilly awarded more than $458 million to 19 Indiana colleges and universities across two rounds.
Community investmentConfirmedIn favor
Lilly commits to 500k meals and cold storage for 150 food pantries
Lilly commits to support community organizations providing 500,000 meals and cold storage for 150 food pantries.
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries
Workplace equitySettlementAgainst
Lilly USA was sued by the EEOC for nationwide age discrimination
Lilly USA Sued by EEOC for Nationwide Age Discrimination.
Lilly USA Sued by EEOC for Nationwide Age Discrimination
Lilly USA Sued by EEOC for Nationwide Age Discrimination | U.S. Equal Employment Opportunity Commission
The EEOC filed suit in the U.S. District Court for the Southern District of Indiana, Indianapolis Division (EEOC v. Lilly USA, LLC, Case No. 1-22-cv-01882) after first attempting to reach a pre-litigation settlement through its conciliation process.
Corporate conductSettlementAgainst
Lilly settles over consumer calling ban
Lilly settles after being prohibited from calling consumers who requested no further contact.
The FTC’s complaint charges Lilly and Kevin W. Lawrence with violating the TSR by making millions of illegal robocalls to sell packages offered by a number of vacation package companies.
The settlement also prohibits Lilly and Lawrence from calling consumers who have asked that they not be called again.
Privacy & surveillanceProposed settlementAgainst
Lilly settled FTC charges concerning a security breach involving the unauthorized disclosure of sensitive personal information
Eli Lilly Settles FTC Charges Concerning Security Breach.
The FTC complaint alleges that Lilly's claim of privacy and confidentiality was deceptive because Lilly failed to maintain or implement internal measures appropriate under the circumstances to protect sensitive consumer information, which led to the company's unintentional June 27th disclosure of Medi-messenger subscribers' personal information (i.e., e-mail addresses).
"Lilly's responsiveness," he stated, "and its efforts to improve corporate privacy practices can be a model for others to follow."
Eli Lilly Settles FTC Charges Concerning Security Breach
As part of the settlement, Lilly will take appropriate security measures to protect consumers' privacy.
Eli Lilly and Company (Lilly) has agreed to settle Federal Trade Commission charges regarding the unauthorized disclosure of sensitive personal information collected from consumers through its Prozac.com Web site.
Lilly should be respected for its long-standing efforts in development of its privacy practices, its acceptance of responsibility for the internal failures that resulted in the alleged violation of its privacy policy, and its willingness to take appropriate steps to correct those mistakes." Commissioner Swindle stated that he appreciates the company's leadership in cooperating with the FTC to improve its security measures, and he believes the firm will carry out fully its commitments under the proposed order.
Additionally, Lilly would be required to establish and maintain a four-stage information security program designed to establish and maintain reasonable and appropriate administrative, technical, and physical safeguards to protect consumers' personal information against any reasonably anticipated threats or hazards to its security, confidentiality, or integrity, and to protect such information against unauthorized access, use, or disclosure.
In fact, according to the complaint, Lilly failed to: provide appropriate training for its employees regarding consumer privacy and information security; provide appropriate oversight and assistance for the employee who sent out the e-mail, who had no prior experience in creating, testing, or implementing the computer program used; and implement appropriate checks and controls on the process, such as reviewing the computer program with experienced personnel and pretesting the program internally before sending out the e-mail.
He said that "Lilly's unfortunate and unintended disclosure of prescription drug users' personal information has given us all the opportunity to evaluate how to improve upon security practices for confidential information.
Corporate conductAllegationAgainst
Lilly is accused of bribing providers
Lilly is accused of bribing providers to prescribe its medications.
WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications.
Corporate conductConfirmedAgainst
Lilly exploits safety-net hospitals
Lilly is accused of exploiting safety-net hospitals and abusing market power, harming Florida residents.
Tampa General said in the complaint that it was taking the action due to Eli Lilly's "exploitation of safety-net hospitals, abuse of market power, and mistreatment of Florida residents."
Corporate conductRulingAgainst
Eli Lilly was accused of defrauding Medicaid
A federal appeals court on Thursday rejected Eli Lilly's appeal of an $183.7 million judgment won by a whistleblowing lawyer and pharmacist who accused the drugmaker of defrauding Medicaid.
Jurors ordered Indianapolis-based Lilly to pay $61.23 million in August 2022, which the trial judge tripled to $183.7 million under the False Claims Act.
A federal appeals court on Thursday rejected Eli Lilly's appeal of an $183.7 million judgment won by a whistleblowing lawyer and pharmacist who accused the drugmaker of defrauding Medicaid.
Eli Lilly loses appeal of $183.7 million Medicaid fraud award
The three-judge appeals court panel also rejected whistleblower Ronald Streck's claim that the judgment should have been higher because the trial judge undercounted Lilly's violations of the federal False Claims Act.
Circuit Court of Appeals in Chicago said a federal jury reasonably found that Lilly knowingly concealed having retroactively increased prices on some drugs, and then failing to rebate Medicaid on the higher prices.
Following discovery, Streck and Lilly cross-moved for summary judgment.
But the most the agency charged with administering the program would tell them is to make “reasonable assumptions.” Lacking any more clarity than that, Lilly and several other manufacturers concluded that certain adjustments to fees owed to wholesalers (and vice versa) should not be included when calculating AMP.
He a lleged that Lilly’s falsely lowered AMPs between 2005 and 2017 led to $61 million in Medicaid underpayments, violating the FCA, see 31 U.S.C.
While the court framed that discussion as an inquiry into “The Reasonableness of Lilly ’s AMP Calculation,” Pet.App.17, at no point did it explain what makes a legal interpretation “objectively unreasonable.” And while the court acknowledged that the Third Circuit had previously held that the very same interpretation of the Medicaid Act that Lilly (told the government it) used was at least reasonabl e, it rejected the Third Circuit’s conclusion for the same reasons that it held Lilly’s reading to be incorrect.
Both Streck and Lilly moved for summary judgment.
Defendant Lilly moves for full summary judgment against the Relator, arguing caselaw establishes affirmative defenses that prevent liability.
Circuit Court of Appeals in Chicago said a federal jury reasonably found that Lilly knowingly concealed having retroactively increased prices on some drugs, and then failing to rebate Medicaid on the higher prices.
(Reuters) - A federal appeals court on Thursday rejected Eli Lilly's appeal of an $183.7 million judgment won by a whistleblowing lawyer and pharmacist who accused the drugmaker of defrauding Medicaid.
Circuit Judge Joshua Kolar said jurors heard "ample evidence" suggesting that Lilly "was aware of, or disregarded, an unjustifiable risk of skirting the law and chose to obfuscate rather than conduct a reasonable inquiry."
Workplace equitySettlementAgainst
Lilly settles age discrimination lawsuit
Lilly agrees to pay $2.4 million to settle a nationwide EEOC age discrimination lawsuit.
In addition to the monetary relief, the decree requires Lilly to provide EEO training to certain managers and human resources personnel, survey job applicants on whether they experienced discrimination, and specifically state in contracts with third-party recruiters that it does not discriminate against candidates for employment based upon age.
Lilly to Pay $2.4 Million to Settle Nationwide EEOC Age Discrimination Lawsuit | U.S. Equal Employment Opportunity Commission
The EEOC’s lawsuit sought relief for pharmaceutical sales representative applicants who were denied positions due to Lilly’s “Early Career” hiring initiative.
Lilly to Pay $2.4 Million to Settle Nationwide EEOC Age Discrimination Lawsuit
INDIANAPOLIS – Lilly USA, LLC, a pharmaceutical corporation based in Indianapolis, Indiana, and its parent company, Eli Lilly and Company, will pay $2.4 million and provide other equitable relief to settle a nationwide class age discrimination lawsuit brought by the U.S. Equal Employment Opportunity Commission (EEOC), the federal agency announced today.
According to the EEOC’s suit, in 2017, Lilly’s senior vice president for human resources and diversity recognized at a Leadership Town Hall that Lilly’s workforce was composed of older workers.
Corporate conductSettlementAgainst
Lilly settles corrupt foreign practices complaint
Lilly settles for $29.4 million over foreign bribery allegations.
Eli Lilly settles corrupt foreign practices complaint for $29.4m
Eli Lilly settles corrupt foreign practices complaint for $29.4m | The BMJ
The drug company Eli Lilly and Co has agreed to a $29.4m (£18.2m; €22.3m) settlement with the US Securities and Exchange Commission for violation of the US Foreign Corrupt Practices Act in a legal agreement signed on 20 December.1 The 1977 antibribery act made it “unlawful for certain classes of persons and entities to make payments to foreign government officials to assist in obtaining or retaining business.”
Pharmaceutical giant Eli Lilly and Co. agreed December 20 to pay $29.4 million to settle charges by the U.S. Securities and Exchange Commission that it violated the ...
Pharmaceutical giant Eli Lilly and Co. agreed December 20 to pay $29.4 million to settle charges by the U.S. Securities and Exchange Commission that it violated the Foreign Corrupt Practices Act by making improper payments to officials in Russia, Brazil, China and Poland.
Lilly agreed to pay disgorgement of $13,955,196, prejudgment interest of $6,743,538, and a penalty of $8,700,000 for a total payment of $29,398,734.
The Securities and Exchange Commission today charged Eli Lilly and Company with violations of the Foreign Corrupt Practices Act (FCPA) for improper payments its subsidiaries made to foreign government officials to win millions of dollars of business in Russia, Brazil, China and Poland.
Lilly agreed to pay more than $29 million to settle the SEC's charges.
SEC FILES SETTLED FCPA CHARGES AGAINST ELI LILLY AND COMPANY
Lilly's subsidiary in Poland made eight improper payments totaling $39,000 to a small charitable foundation that was founded and administered by the head of one of the regional government health authorities in exchange for the official's support for placing Lilly drugs on the government reimbursement list.
Lilly's subsidiary in Brazil allowed one of its pharmaceutical distributors to pay bribes to government health officials to facilitate $1.2 million in sales of a Lilly drug product to state government institutions.
Without admitting or denying the allegations, Lilly consented to the entry of a final judgment permanently enjoining the company from violating the anti-bribery, books and records, and internal controls provisions of the FCPA, Sections 30A, 13(b)(2)(A) and 13(b)(2)(B) of the Securities Exchange Act.
Employees at Lilly's subsidiary in China falsified expense reports in order to provide spa treatments, jewelry, and other improper gifts and cash payments to government-employed physicians.
Lilly agreed to pay more than $29 million to settle the SEC’s charges.
Lilly’s subsidiary in Brazil allowed one of its pharmaceutical distributors to pay bribes to government health officials to facilitate $1.2 million in sales of a Lilly drug product to state government institutions.
Lilly agreed to pay disgorgement of $13,955,196, prejudgment interest of $6,743,538, and a penalty of $8.7 million for a total payment of $29,398,734.
The Securities and Exchange Commission today charged Eli Lilly and Company with violations of the Foreign Corrupt Practices Act (FCPA) for improper payments its subsidiaries made to foreign government officials to win millions of dollars of business in Russia, Brazil, China, and Poland.
SEC Charges Eli Lilly and Company with FCPA Violations
The SEC alleges that when the company did become aware of possible FCPA violations in Russia, Lilly did not curtail the subsidiary’s use of the marketing agreements for more than five years.
Corporate conductConfirmedAgainst
Lilly to credit or refund overcharges
Lilly is required to credit or refund all covered entities for overcharges from its 340B ceiling price policy.
The May 17 Letter instructed Lilly to "immediately begin offering its covered outpatient drugs at the 340B ceiling price to covered entities through their contract pharmacy arrangements" and to "credit or refund all covered entities for overcharges that have resulted from Lilly's policy."
16 Five days later, on May 17, 2021, HRSA issued a 340B-violation letter (the "May 17 Letter") notifying Lilly that, after a comprehensive and months' long review of Lilly's contract pharmacy policy, "HRSA has determined that Lilly's actions have resulted in overcharges and are in direct violation of the 340B statute." May 17, 2021 Letter.
Corporate conductConfirmedAgainst
Lilly charged with improper payments to foreign officials
Lilly was charged by SEC for improper payments to foreign government officials to win business in Russia, Brazil, China, and Poland.
Eli Lilly and Company - SEC charged the Indianapolis-based pharmaceutical company for improper payments its subsidiaries made to foreign government officials to win business in Russia, Brazil, China, and Poland.
Eli Lilly Settles SEC Case Involving Bribery Violations | Law.com
Eli Lilly Settles SEC Case Involving Bribery Violations
Reproductive careConfirmedYou decide
Eli Lilly spent an average of $8,549,018 per year on federal lobbying between 2008 and 2017
Although the full amounts that would be disclosed if the company complied with the requests of the Proposal are unknown, viewing the federally disclosed spending by the Company, between 2008 and 2017, Eli Lilly spent an average of $8,549,018 per year on federal lobbying, according to OpenSecrets.org.
to lower prescription drug prices.4 Lilly opposed Indiana voter restrictions, yet groups have asked Lilly to cut ties with the American Legislative Exchange Council (ALEC) “because of its voter restriction efforts.”5 Lilly is also represented at ALEC by its trade associations, as the Chamber, NAM and PhRMA each sit on its Private Enterprise Advisory Council.
Lilly fails to disclose its third-party payments to trade associations and social welfare groups (SWGs), or the amounts used for lobbying, to shareholders.
Supporting Statement: In 2022, Eli Lilly made clear its opposition to an Indiana law that restricts abortion in cases other than rape, incest, or where a woman’s life is in danger.15 The Company claimed that as a result of this law, its ability to attract diverse employees would be hindered, and that it would be “forced to plan for more employment growth outside our home state.” 16 The Company also said it expanded its employee health plan coverage to include travel for abortion.17
However, there is not just one gap but several between Eli Lilly’s current disclosures on this subject and the Proposal’s request for comprehensive lobbying disclosure.
Although the full amounts that would be disclosed if the company complied with the requests of the Proposal are unknown, viewing the federally disclosed spending by the Company, between 2008 and 2017, Eli Lilly spent an average of $8,549,018 per year on federal lobbying, according to OpenSecrets.org.
ManufacturingConfirmedYou decide
Lilly invests $750 million in U.S. drug manufacturing
Lilly invests $750 million to expand U.S. drug manufacturing.
Eli Lilly unveils $27bn US investment as corporate America seeks to woo Trump – The Irish Times
Corporate conductConfirmedAgainst
Lilly discloses DOJ subpoena for Branchburg factory
Lilly disclosed in a securities filing that it received a subpoena from the Justice Department in May seeking documents related to the Branchburg factory.
Reuters questioned Lilly about the criminal inquiry on Wednesday. On Thursday morning, the company disclosed in a securities filing that it had received a subpoena from the Justice Department in May seeking documents related to the Branchburg factory.
Corporate conductConfirmedAgainst
Lilly rebuffed by Supreme Court on $194 Million Medicaid award
Lilly was rebuffed by the Supreme Court regarding a $194 million Medicaid award.
A lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which confuses consumers by using outdated studies to compare the highest injectable doses of Lilly's medicines against lower doses of Novo Nordisk's injectable medicines for obesity and type 2 diabetes
Two of the world's biggest pharmaceutical companies are headed to court after Novo Nordisk, the maker of Ozempic and a pioneer in diabetes and obesity treatments, sued rival Eli Lilly on Tuesday, accusing the U.S. drugmaker of false advertising.
(www.nbcnews.com/health/health- news/several-probes-target-insulin-drug-pricing-n815141; www.bloomberg.com/news/articles/2017-06-29/the-crazy-math-behind-drug-prices) Frequent press coverage has focused on Eli Lilly’s prices and price increases, with headlines like “Eli Lilly’s Revenue Boosted by Jacking Up Cost of Insulin for Diabetics” and “Skyrocketing Insulin Prices Force Some to Choose Between Medicine and Food.” (www.marketwatch.com/story/eli-lillys-revenue-boosted-by- higher-drug-prices-for-diabetics-2016-01-28; www.wtae.com/article/skyrocketing-insulin- prices-force-some-to-choose-between-medicine-and-food/9588176; see also www.cbsnews.com/news/insulin-prices-rise-yet-again-causing-diabetics-to-cry-foul/; https://www.cnbc.com/2017/05/10/eli-lilly-raised-prices-on- 9-drugs-last-week.html; https://www.wthr.com/article/rising-insulin-prices-forcing-hoosiers-with- diabetes-to-make-tough-choices) In September 2017, patients protested high insulin prices at Eli Lilly’s headquarters, demanding not only lower prices but also fuller disclosure regarding costs and profits.
For type 2 diabetes, Lilly’s Mounjaro® ads falsely tell c onsumers that its Mounjaro® brand reduces A1c (a key measure of blood sugar control for patients with type 2 diabetes) significantly more than Novo Nordisk’s competing brand of type 2 diabetes medicine, Ozempic®.
Corporate conductSettlementAgainst
Eli Lilly and Company pleaded guilty to a violation of the Federal Food, Drug, and Cosmetic Act
On January 30, 2009, Eli Lilly and Company pleaded guilty to a violation of the Federal Food, Drug, and Cosmetic Act.
To resolve these matters, Lilly pled guilty to a misdemeanor criminal violation of the Federal Food Drug and Cosmetic Act and agreed to pay more than $ 1 billion to the Federal Governent and state Medicaid programs.